AU2001236440A1 - Method for the treatment of inflammation with spla2 inhibitors - Google Patents

Method for the treatment of inflammation with spla2 inhibitors

Info

Publication number
AU2001236440A1
AU2001236440A1 AU2001236440A AU3644001A AU2001236440A1 AU 2001236440 A1 AU2001236440 A1 AU 2001236440A1 AU 2001236440 A AU2001236440 A AU 2001236440A AU 3644001 A AU3644001 A AU 3644001A AU 2001236440 A1 AU2001236440 A1 AU 2001236440A1
Authority
AU
Australia
Prior art keywords
inflammation
treatment
spla2 inhibitors
spla2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236440A
Inventor
Jerome Herbert Fleisch
William Louis Macias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001236440A1 publication Critical patent/AU2001236440A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
AU2001236440A 2000-01-25 2001-01-16 Method for the treatment of inflammation with spla2 inhibitors Abandoned AU2001236440A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17790700P 2000-01-25 2000-01-25
US60177907 2000-01-25
PCT/US2001/000011 WO2001055108A2 (en) 2000-01-25 2001-01-16 Use of spl a2 inhibitors for the treatment of inflammation

Publications (1)

Publication Number Publication Date
AU2001236440A1 true AU2001236440A1 (en) 2001-08-07

Family

ID=22650407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236440A Abandoned AU2001236440A1 (en) 2000-01-25 2001-01-16 Method for the treatment of inflammation with spla2 inhibitors

Country Status (2)

Country Link
AU (1) AU2001236440A1 (en)
WO (1) WO2001055108A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003966A1 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
EA200971020A1 (en) * 2007-05-03 2010-10-29 Антера Фармасьютикалз, Инк. TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA WITH THE USE OF SECRETARY PHOSPHOLIPASE A SPLA INHIBITORS AND SPLA INHIBITOR TREATMENT METHODS
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
US6166062A (en) * 1998-03-03 2000-12-26 Shionogi & Co., Ltd. Pharmaceutical compositions containing phospholipase inhibitor
ID27153A (en) * 1998-05-01 2001-03-08 Lilly Co Eli SPLA2 INHIBITOR COMPOUNDS TO TREAT DISEASE
WO2000002561A1 (en) * 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6608099B1 (en) * 1998-08-03 2003-08-19 Eli Lilly And Company Indole sPLA2 inhibitors
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
RU2189961C2 (en) * 1999-07-19 2002-09-27 Карапетян Гарегин Оганесович Method of immobilization of physiologically active compounds

Also Published As

Publication number Publication date
WO2001055108A2 (en) 2001-08-02
WO2001055108A3 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001234088A1 (en) TNF-alpha inhibitors
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001286983A1 (en) Method of treatment
AU2001285747A1 (en) Method for the treatment of tobacco
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2002350319A1 (en) Method and system for the treatment of wastewater
AU2003240668A1 (en) Attenuation of metapneumovirus
AU2001287668A1 (en) Method for the sterilisation of objects
AU2003260778A1 (en) Treatment of pipes
AU2001237536A1 (en) Method and apparatus for the clearing of minefields
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002224550A1 (en) Corrosion inhibitors
IL155769A0 (en) Method for the treatment of inflammation
AU2001236440A1 (en) Method for the treatment of inflammation with spla2 inhibitors
AU2001241630A1 (en) Treatment of inflammation with p20
AU2001262177A1 (en) Method of treatment
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2002305868A1 (en) Inhibitors of reggamma
AU2003216312A1 (en) NON-COVALENT INHIBITORS OF AmpC ss-LACTAMASE
AU4598400A (en) Method of treatment
AU2003210741A1 (en) Ptpase inhibitors and methods of using the same